PSHP President’s Update PSHP Annual Assembly
PT
Published · 56 slides · 0 views
1 / 1
Description
PSHP Presidents Update PSHP Annual Assembly October 28, 2015 Matt Scola, PharmD, MHA Pharmacist Learning Objectives Describe the current state and future direction of PSHP Summarize key points from the ASHP House of Delegates meeting
Related Topics
Share
Embed code
Download this presentation From Below
"PSHP President’s Update PSHP Annual Assembly" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
01
PSHP President’s Update PSHP Annual Assembly
October 28, 2015
Matt Scola, PharmD, MHA<br>
October 28, 2015
Matt Scola, PharmD, MHA<br>
02
Pharmacist Learning Objectives Describe the current state and future direction of PSHP
Summarize key points from the ASHP House of Delegates meeting
Discuss current trends in pharmacy practice
Review components of the Pennsylvania Pharmacy Technician bill<br>
Summarize key points from the ASHP House of Delegates meeting
Discuss current trends in pharmacy practice
Review components of the Pennsylvania Pharmacy Technician bill<br>
03
Pharmacy Technician Learning Objectives Describe the current state and future direction of PSHP
Summarize key points from the ASHP House of Delegates meeting
Discuss current trends in pharmacy practice and opportunities for technicians
Review components of the Pennsylvania Pharmacy Technician bill<br>
Summarize key points from the ASHP House of Delegates meeting
Discuss current trends in pharmacy practice and opportunities for technicians
Review components of the Pennsylvania Pharmacy Technician bill<br>
04
PSHP Current State Monthly Board of Directors meetings
Strategic planning session prior to last year’s Annual Assembly
Strategic Planning session prior to this meeting
Membership Committee, Public Relations Committee
~500 active members<br>
Strategic planning session prior to last year’s Annual Assembly
Strategic Planning session prior to this meeting
Membership Committee, Public Relations Committee
~500 active members<br>
05
2015-2016 Officers Past-President- Jennifer Belavic
President- Matt Scola
President Elect- Bill O’Hara
Treasurer- Dave Cecere
Board Members
Elaine Strauss
Brad Cooper
Jill Rebuck
Lynne Byrne<br>
President- Matt Scola
President Elect- Bill O’Hara
Treasurer- Dave Cecere
Board Members
Elaine Strauss
Brad Cooper
Jill Rebuck
Lynne Byrne<br>
06
Able Management 8/3/07- Contract signed between PSHP and Able Management
7/10- PSHP notifies Able of intent not to renew contract
11/1/10- Contract between Able and PSHP supposed to end
3/31/11- Last communication from Able management<br>
7/10- PSHP notifies Able of intent not to renew contract
11/1/10- Contract between Able and PSHP supposed to end
3/31/11- Last communication from Able management<br>
07
Able Management 2/11 through 7/11- Able withdraws ~$99,000 from PSHP accounts
8/11-Audit conducted of 2010 finances plus acquisition of detailed transactions for 2011
1/12- initial discussions with legal representation
3/13- draft complaint created<br>
8/11-Audit conducted of 2010 finances plus acquisition of detailed transactions for 2011
1/12- initial discussions with legal representation
3/13- draft complaint created<br>
08
Able Management 12/30/13- complaint filed
6/10/14- notice sent to Defendant
11/18/14- default judgement granted
12/19/14- Damages hearing
12/30/14- Decision of damages granted- ~109,720 ($99k plus interest)
3/27/15- Judgements of lien on file in both Franklin and Delaware County (OH)<br>
6/10/14- notice sent to Defendant
11/18/14- default judgement granted
12/19/14- Damages hearing
12/30/14- Decision of damages granted- ~109,720 ($99k plus interest)
3/27/15- Judgements of lien on file in both Franklin and Delaware County (OH)<br>
09
Able Management As of 8/5/15- no assets on record for either Able Management or former owner
Judge’s decision good for 5 yrs
Can renew/extend judgement
Good in both Franklin and Delaware counties (OH)
Could set up judgement debtor exam
Requires previous owner to show up in court
Result depends on cash assets
Low probability of success<br>
Judge’s decision good for 5 yrs
Can renew/extend judgement
Good in both Franklin and Delaware counties (OH)
Could set up judgement debtor exam
Requires previous owner to show up in court
Result depends on cash assets
Low probability of success<br>
10
Strategic Planning Overview 2012 event
Focused on business model
Goal= stabilize
Jan. 2014 event
Developing a 3 yr plan
Creating more outreach
Develop future structure
Oct. 2014 event
Broadening of previous work into overarching goal structure<br>
Focused on business model
Goal= stabilize
Jan. 2014 event
Developing a 3 yr plan
Creating more outreach
Develop future structure
Oct. 2014 event
Broadening of previous work into overarching goal structure<br>
11
PSHP Current State Attendance at ASHP Presidential Officer’s Retreat
One of two regional meetings help
~40 attendees- officers, executives
Focus on membership discussions- attraction and retention
Brief discussions on ASHP’s Ambulatory Care Summit<br>
One of two regional meetings help
~40 attendees- officers, executives
Focus on membership discussions- attraction and retention
Brief discussions on ASHP’s Ambulatory Care Summit<br>
12
PSHP Current State Increased social media presence
Facebook and LinkedIn
Member profiles in newsletters
Overall newsletter content
“Get a Member” campaign
Efforts to re-establish Western Chapter
Northcentral and Southcentral still inactive<br>
Facebook and LinkedIn
Member profiles in newsletters
Overall newsletter content
“Get a Member” campaign
Efforts to re-establish Western Chapter
Northcentral and Southcentral still inactive<br>
13
PSHP Finances<br>
14
PSHP- Next steps Membership
Ongoing actions to increase membership numbers and maintain member retention
Legislative actions
Increasing presence and actions relative to legislation impacting profession<br>
Ongoing actions to increase membership numbers and maintain member retention
Legislative actions
Increasing presence and actions relative to legislation impacting profession<br>
15
ASHP House of Delegates Last met in June 2015
Over 30 policies reviewed and voted upon
Sample Topics
Provider status
Insurance/coverage issues
Substance abuse
Capital punishment
Biosimilars<br>
Over 30 policies reviewed and voted upon
Sample Topics
Provider status
Insurance/coverage issues
Substance abuse
Capital punishment
Biosimilars<br>
16
ASHP Policy Process<br>
17
1502 - Pharmacist Recognition as a Healthcare Provider Source: Council on Public Policy
To advocate for changes in federal (e.g., Social Security Act), state, and third-party payment programs to define pharmacists as healthcare providers; further,
To affirm that pharmacists, as medication-use experts, provide safe, accessible, high-quality care that is cost effective, resulting in improved patient outcomes; further,
To recognize that pharmacists, as healthcare providers, improve access to patient care and bridge existing gaps in healthcare; further,
To collaborate with key stakeholders to describe the covered direct patient-care services provided by pharmacists; further,<br>
To advocate for changes in federal (e.g., Social Security Act), state, and third-party payment programs to define pharmacists as healthcare providers; further,
To affirm that pharmacists, as medication-use experts, provide safe, accessible, high-quality care that is cost effective, resulting in improved patient outcomes; further,
To recognize that pharmacists, as healthcare providers, improve access to patient care and bridge existing gaps in healthcare; further,
To collaborate with key stakeholders to describe the covered direct patient-care services provided by pharmacists; further,<br>
18
1502 - Pharmacist Recognition as a Healthcare Provider (cont’d) To advocate for sustainable compensation and standardized billing processes used by payers for pharmacist services by all available payment programs.
This policy supersedes ASHP policy 1307.<br>
This policy supersedes ASHP policy 1307.<br>
19
1503 - Pharmaceutical Product and Supply Chain Integrity Source: Council on Public Policy
To encourage the Food and Drug Administration (FDA) and relevant state authorities to take the steps necessary to ensure that (1) all drug products entering the supply chain are thoroughly inspected and tested to establish that they have not been adulterated or misbranded and (2) patients will not receive improperly labeled and packaged, deteriorated, outdated, counterfeit, adulterated, or unapproved drug products; further,
To encourage FDA and relevant state authorities to develop and implement regulations to (1) restrict or prohibit licensed drug distributors (drug wholesalers, repackagers, and manufacturers) from purchasing legend drugs from unlicensed entities and (2) ensure accurate documentation at any point in the distribution chain of the original source of drug products and chain of custody from the manufacturer to the pharmacy; further,<br>
To encourage the Food and Drug Administration (FDA) and relevant state authorities to take the steps necessary to ensure that (1) all drug products entering the supply chain are thoroughly inspected and tested to establish that they have not been adulterated or misbranded and (2) patients will not receive improperly labeled and packaged, deteriorated, outdated, counterfeit, adulterated, or unapproved drug products; further,
To encourage FDA and relevant state authorities to develop and implement regulations to (1) restrict or prohibit licensed drug distributors (drug wholesalers, repackagers, and manufacturers) from purchasing legend drugs from unlicensed entities and (2) ensure accurate documentation at any point in the distribution chain of the original source of drug products and chain of custody from the manufacturer to the pharmacy; further,<br>
20
1503 - Pharmaceutical Product and Supply Chain Integrity (cont’d) To advocate for the establishment of meaningful penalties for companies that violate current good manufacturing practices (cGMPs) intended to ensure the quality, identity, strength, and purity of their marketed drug product(s) and raw materials; further,
To advocate for improved transparency so that drug product labeling include a readily available means to retrieve the name and location of the facility that manufactured the specific lot of the product; further,
To advocate that this readily retrievable manufacturing information be available prospectively to aid purchasers in determining the quality of a drug product and its raw materials; further,
To urge Congress and state legislatures to provide adequate funding, or authority to impose user fees, to accomplish these objectives.
This policy supersedes ASHP policy 0907.<br>
To advocate for improved transparency so that drug product labeling include a readily available means to retrieve the name and location of the facility that manufactured the specific lot of the product; further,
To advocate that this readily retrievable manufacturing information be available prospectively to aid purchasers in determining the quality of a drug product and its raw materials; further,
To urge Congress and state legislatures to provide adequate funding, or authority to impose user fees, to accomplish these objectives.
This policy supersedes ASHP policy 0907.<br>
21
1509 - Approval of Biosimilar Medications Source: Council on Public Policy
To encourage the development of safe and effective biosimilar medications in order to make such medications more affordable and accessible; further,
To encourage research on the safety, effectiveness, and interchangeability of biosimilar medications; further,
To support legislation and regulation to allow Food and Drug Administration (FDA) approval of biosimilar medications; further,
To support legislation and regulation to allow FDA approval of biosimilar medications that are also determined by the FDA to be interchangeable and therefore may be substituted for the reference product without the intervention of the prescriber; further,<br>
To encourage the development of safe and effective biosimilar medications in order to make such medications more affordable and accessible; further,
To encourage research on the safety, effectiveness, and interchangeability of biosimilar medications; further,
To support legislation and regulation to allow Food and Drug Administration (FDA) approval of biosimilar medications; further,
To support legislation and regulation to allow FDA approval of biosimilar medications that are also determined by the FDA to be interchangeable and therefore may be substituted for the reference product without the intervention of the prescriber; further,<br>
22
1509 - Approval of Biosimilar Medications (cont’d) To oppose the implementation of any state laws regarding biosimilar interchangeability prior to finalization of FDA guidance; further,
To oppose any state legislation that would require a pharmacist to notify a prescriber when a biosimilar deemed to be interchangeable by the FDA is dispensed; further,
To require postmarketing surveillance for all biosimilar medications to ensure their continued safety, effectiveness, purity, quality, identity, and strength; further,
To advocate for adequate reimbursement for biosimilar medications that are deemed interchangeable; further,<br>
To oppose any state legislation that would require a pharmacist to notify a prescriber when a biosimilar deemed to be interchangeable by the FDA is dispensed; further,
To require postmarketing surveillance for all biosimilar medications to ensure their continued safety, effectiveness, purity, quality, identity, and strength; further,
To advocate for adequate reimbursement for biosimilar medications that are deemed interchangeable; further,<br>
23
1509 - Approval of Biosimilar Medications (cont’d) To promote and develop ASHP-directed education of pharmacists about biosimilar medications and their appropriate use within hospitals and health systems; further,
To advocate and encourage pharmacist evaluation and the application of the formulary system before biosimilar medications are used in hospitals and health systems.
This policy supersedes ASHP policy 1409.<br>
To advocate and encourage pharmacist evaluation and the application of the formulary system before biosimilar medications are used in hospitals and health systems.
This policy supersedes ASHP policy 1409.<br>
24
1518 - Developing Leadership Competencies Source: Council on Education and Workforce Development
To work with healthcare organization leadership to foster opportunities for pharmacy practitioners to move into leadership roles; further,
To encourage leaders to seek out and mentor pharmacy practitioners in developing administrative, managerial, and leadership skills; further,
To encourage pharmacy practitioners to obtain the skills necessary to pursue administrative, managerial, and leadership roles; further,
To encourage colleges of pharmacy and ASHP state affiliates to collaborate in fostering student leadership skills through development of co-curricular leadership opportunities, leadership conferences, and other leadership promotion programs; further,<br>
To work with healthcare organization leadership to foster opportunities for pharmacy practitioners to move into leadership roles; further,
To encourage leaders to seek out and mentor pharmacy practitioners in developing administrative, managerial, and leadership skills; further,
To encourage pharmacy practitioners to obtain the skills necessary to pursue administrative, managerial, and leadership roles; further,
To encourage colleges of pharmacy and ASHP state affiliates to collaborate in fostering student leadership skills through development of co-curricular leadership opportunities, leadership conferences, and other leadership promotion programs; further,<br>
25
1518 - Developing Leadership Competencies (cont’d) To reaffirm that residency programs should develop leadership skills through mentoring, training, and leadership opportunities; further,
To foster leadership skills for pharmacists to use on a daily basis in their roles as leaders in patient care.
This policy supersedes ASHP policy 0509.<br>
To foster leadership skills for pharmacists to use on a daily basis in their roles as leaders in patient care.
This policy supersedes ASHP policy 0509.<br>
26
1519 - Pharmacy Technician Training and Certification Source: Council on Education and Workforce Development
To support the position that by the year 2020, the completion of a pharmacy technician training program accredited by ASHP and the Accreditation Council for Pharmacy Education (ACPE) be required to obtain Pharmacy Technician Certification Board certification for all new pharmacy technicians entering the workforce; further,
To foster expansion of ASHP-ACPE accredited pharmacy technician training programs.
This policy supersedes ASHP policies 1015 and 0702.<br>
To support the position that by the year 2020, the completion of a pharmacy technician training program accredited by ASHP and the Accreditation Council for Pharmacy Education (ACPE) be required to obtain Pharmacy Technician Certification Board certification for all new pharmacy technicians entering the workforce; further,
To foster expansion of ASHP-ACPE accredited pharmacy technician training programs.
This policy supersedes ASHP policies 1015 and 0702.<br>
27
ASHP House of Delegates New process underway
Shift towards perpetual process-more responsive process
Focus on online commenting procedures
Changes in election timing
First virtual voting to occur in November
Allows voting and passage of updates throughout the year
Still having onsite HOD at Annual Meeting<br>
Shift towards perpetual process-more responsive process
Focus on online commenting procedures
Changes in election timing
First virtual voting to occur in November
Allows voting and passage of updates throughout the year
Still having onsite HOD at Annual Meeting<br>
28
2015-2016 Delegates Nishaminy Kasbekar
Patricia Kienle
Bill O’Hara
Jean Schultz
Matt Scola
Alternates
Jennifer Belavic
Thao Huynh
Richard Pacitti<br>
Patricia Kienle
Bill O’Hara
Jean Schultz
Matt Scola
Alternates
Jennifer Belavic
Thao Huynh
Richard Pacitti<br>
29
Current Trends in Pharmacy Practice Provider Status
Drug Supply Chain Security Act
Transitions of Care
340B Regulations
USP 800<br>
Drug Supply Chain Security Act
Transitions of Care
340B Regulations
USP 800<br>
30
Pharmacist Provider Status Pharmacists continue to lack recognition as health care providers in federal law
Current push to amend the Social Security Act to allow Medicare beneficiaries to access pharmacist provided services under Medicare Part B<br>
Current push to amend the Social Security Act to allow Medicare beneficiaries to access pharmacist provided services under Medicare Part B<br>
31
Pharmacy and Medically Underserved Areas Enhancement Act HR 592 & S314
Would allow for payment (and recognition as provider) for pharmacy services furnished by a licensed pharmacist
Legally allowed to provide the service
Service would be otherwise covered if provided by a physician or incident to
Occurs in medically underserved areas or medically underserved population<br>
Would allow for payment (and recognition as provider) for pharmacy services furnished by a licensed pharmacist
Legally allowed to provide the service
Service would be otherwise covered if provided by a physician or incident to
Occurs in medically underserved areas or medically underserved population<br>
32
Pharmacy and Medically Underserved Areas Enhancement Act Allows for payment of 80% of total charge or 85% of established fee, whichever is less
225 cosponsors in the House (out of 435)
33 cosponsors in the Senate<br>
225 cosponsors in the House (out of 435)
33 cosponsors in the Senate<br>
33
Pharmacy and Medically Underserved Areas Enhancement Act Pennsylvania Representatives supporting:
Barletta
Cartwright
Costello
Dent
Doyle
Meehan
Murphy
Perry
Shuster
Thompson<br>
Barletta
Cartwright
Costello
Dent
Doyle
Meehan
Murphy
Perry
Shuster
Thompson<br>
34
Pharmacy and Medically Underserved Areas Enhancement Act Pennsylvania Representatives NOT supporting:
Boyle
Brady
Fattah
Fitzpatrick
Kelly
Marino
Pitts
Rothfus<br>
Boyle
Brady
Fattah
Fitzpatrick
Kelly
Marino
Pitts
Rothfus<br>
35
Pharmacy and Medically Underserved Areas Enhancement Act PA Senators stance:
Casey- Cosponsor
Toomey- not yet sponsored<br>
Casey- Cosponsor
Toomey- not yet sponsored<br>
36
Pharmacist Provider Status Resources
Patient Access to Pharmacists’ Care Coalition- http://www.pharmacistscare.org
ASHP- http://www.ashp.org/
APhA- http://www.pharmacist.com
US Congress- http://www.congress.gov<br>
Patient Access to Pharmacists’ Care Coalition- http://www.pharmacistscare.org
ASHP- http://www.ashp.org/
APhA- http://www.pharmacist.com
US Congress- http://www.congress.gov<br>
37
Drug Supply Chain Security Act (DSCSA) Part of the Drug Quality and Security Act- signed into federal law on 11/17/13
Outlines critical steps to build an electronic, interoperable system to identify and trace certain prescription drugs
10 year implementation phase
Facilitate exchange of information at the individual package level about where in the supply chain a drug has been<br>
Outlines critical steps to build an electronic, interoperable system to identify and trace certain prescription drugs
10 year implementation phase
Facilitate exchange of information at the individual package level about where in the supply chain a drug has been<br>
38
DSCSA The electronic system will
Enable verification and legitimacy of drug product verification to the package level
Enhance detection and notification of illegitimate products
Facilitate more efficient drug recalls
Impacts manufacturers (M), repackagers (R), wholesale drug distributors (W) and dispensers (D)
Does not apply to reverse distributors<br>
Enable verification and legitimacy of drug product verification to the package level
Enhance detection and notification of illegitimate products
Facilitate more efficient drug recalls
Impacts manufacturers (M), repackagers (R), wholesale drug distributors (W) and dispensers (D)
Does not apply to reverse distributors<br>
39
DSCSA- Key Provisions M & R put unique product identifiers on certain packages
M, W, R, & many D’s provide information about a drug and who handled it each time it is sold
M, W, R, & many D’s establish systems and processes to be able to verify product identifier on certain prescription products<br>
M, W, R, & many D’s provide information about a drug and who handled it each time it is sold
M, W, R, & many D’s establish systems and processes to be able to verify product identifier on certain prescription products<br>
40
DSCSA- Key Provisions M, W, R & D to quarantine and promptly investigate a drug that has been identified as suspect
M, W, R & D to establish systems and processes to notify FDA and other stakeholders if an illegitimate product is found
W report licensing and contact information to FDA<br>
M, W, R & D to establish systems and processes to notify FDA and other stakeholders if an illegitimate product is found
W report licensing and contact information to FDA<br>
41
DSCSA- Key Provisions Third party logistics providers obtain state or federal license
FDA is charged with oversight of DSCSA
Develop standards
Develop guidance documents
Develop pilot programs
Develop schedule for implementation
Enforcement for implementation delayed from 7/1/15 until 11/1/15<br>
FDA is charged with oversight of DSCSA
Develop standards
Develop guidance documents
Develop pilot programs
Develop schedule for implementation
Enforcement for implementation delayed from 7/1/15 until 11/1/15<br>
42
DSCSA- Requirements for Dispensers Maintain records for 6 years
Transaction information
Transaction history
Transaction statement
Applies to retail and hospital pharmacies
Must provide information to FDA within 2 business days when requested<br>
Transaction information
Transaction history
Transaction statement
Applies to retail and hospital pharmacies
Must provide information to FDA within 2 business days when requested<br>
43
DSCSA-Transaction Information Proprietary or established name
Strength and dosage form
NDC
Container size
Number of containers
Lot Number
Date of transaction
Date of shipment
Business name and address of person to whom ownership is transferred<br>
Strength and dosage form
NDC
Container size
Number of containers
Lot Number
Date of transaction
Date of shipment
Business name and address of person to whom ownership is transferred<br>
44
DSCSA-Transaction Statement Comes from the “seller”
Contains transaction information
Acknowledges “seller” received transaction information and statement from previous owner
Acknowledges “seller” did not knowingly ship counterfeit product
Acknowledges “seller” has systems in place for compliance<br>
Contains transaction information
Acknowledges “seller” received transaction information and statement from previous owner
Acknowledges “seller” did not knowingly ship counterfeit product
Acknowledges “seller” has systems in place for compliance<br>
45
DSCSA- Requirements for Dispensers Does not apply:
Intracompany transfers
Health systems
Public health emergencies
Dispenses to patients
Samples
Medications for office use
Sales to charitable organizations<br>
Intracompany transfers
Health systems
Public health emergencies
Dispenses to patients
Samples
Medications for office use
Sales to charitable organizations<br>
46
Pennsylvania Pharmacy Technician Bill PA has one of the LOWEST grades for technician rules and requirements (http://emilyjerryfoundation.org/ )
Graded as “F”- actual zero points on the scorecard
4 other states listed as “0”
8 states ranked as “F”
18 states ranked as “A” or “B”<br>
Graded as “F”- actual zero points on the scorecard
4 other states listed as “0”
8 states ranked as “F”
18 states ranked as “A” or “B”<br>
47
Pennsylvania Pharmacy Technician Bill HB854- sponsored by Anthony Deluca (D), Allegheny County
Amends Pharmacy Act
Referred to Consumer Protection and Professional Licensure Committee (6/12/15)<br>
Amends Pharmacy Act
Referred to Consumer Protection and Professional Licensure Committee (6/12/15)<br>
48
Pennsylvania Pharmacy Technician Bill D. Costa
Kotik
Thomas
McNeiil
Cohen
Readshaw
Schlossberg Fabrizio
Longietti
Pashinski
Deasy
Barror
Murt
Watson
Gibbons Cosponsors<br>
Kotik
Thomas
McNeiil
Cohen
Readshaw
Schlossberg Fabrizio
Longietti
Pashinski
Deasy
Barror
Murt
Watson
Gibbons Cosponsors<br>
49
Pennsylvania Pharmacy Technician Bill “Pharmacy Technician”- individual who:
Registers with SBOP
May assist in practice of pharmacy under direct and immediate personal supervision of a licensed pharmacist<br>
Registers with SBOP
May assist in practice of pharmacy under direct and immediate personal supervision of a licensed pharmacist<br>
50
Pennsylvania Pharmacy Technician Bill “Pharmacy Technician Trainee”- individual who:
Issued temporary permit by SBOP that authorizes individual to perform duties of Pharmacy Technican<br>
Issued temporary permit by SBOP that authorizes individual to perform duties of Pharmacy Technican<br>
51
Pennsylvania Pharmacy Technician Bill Pharmacy Technician Registration
Register with SBOP biennially
Responsible to licensed pharmacist
At least 17 years of age
High school diploma or equivalent
Completes SBOP approved training program
Completes criminal history background check
Wear name tag identifying individual as Pharmacy Technician<br>
Register with SBOP biennially
Responsible to licensed pharmacist
At least 17 years of age
High school diploma or equivalent
Completes SBOP approved training program
Completes criminal history background check
Wear name tag identifying individual as Pharmacy Technician<br>
52
Pennsylvania Pharmacy Technician Bill SB456- sponsored by John Rafferty, Jr. (R), Berks, Chester and Montgomery counties
Cosponsors
Browne, Tartaglore, Vance
Virtually same language and intent
Suggests annual vs biennial registration<br>
Cosponsors
Browne, Tartaglore, Vance
Virtually same language and intent
Suggests annual vs biennial registration<br>
53
Post Test Questions According to the proposed legislation in both the PA House and Senate, Pharmacy Technicians are required to be PTCB certified
True
False<br>
True
False<br>
54
Post Test Questions The DSCSA only requires transaction information and statements from wholesale drug distributors
True
False<br>
True
False<br>
55
Questions<br>